1. Background
2. Objectives
3. Patients and Methods
3.1. Patients
3.2. Clinical Data
3.3. Fungal Cultures
3.4. In Vitro Antifungal Susceptibility
3.5. Statistical Analysis
4. Results
4.1. Clinical Features Associated With Candidemia
| Patient ID | Age, y | Gender | TBSA, % | Hospital DOS, d | ICU DOS, d | Antibiotic treatment | Mechanical ventilation | Isolated Candida (n) | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 18 | F | 37 | 34 | 18 | + | + | C. tropicalis (1) | survived |
| 2 | 81 | M | 23 | 82 | 75 | + | + | C. guilliermondii (2) | died |
| 3 | 16 | F | 36 | 43 | 40 | + | _ | C. parapsilosis (4) | survived |
| 4 | 54 | F | 21 | 57 | 55 | + | _ | C. parapsilosis (5) | survived |
| 5 | 62 | M | 25 | 50 | 30 | + | _ | C. albicans (1) | died |
| 6 | 27 | F | 54 | 31 | 31 | + | + | C. guilliermondii (2) | died |
| 7 | 8 | M | 66 | 41 | 41 | + | + | C. parapsilosis (2) | survived |
| 8 | 70 | F | 17.5 | 73 | 73 | + | + | C. tropicalis (1) | died |
| 9 | 27 | M | 66 | 29 | 29 | + | + | C. parapsilosis (1); C. tropicalis (1) | died |
| 10 | 26 | M | 52 | 15 | 15 | + | _ | C. tropicalis (2) | died |
| 11 | 30 | F | 25 | 24 | 24 | + | + | C. parapsilosis (1) | died |
| 12 | 18 | F | 60 | 32 | 32 | + | + | C. tropicalis (2) | died |
| 13 | 2 | F | 38 | 25 | 25 | + | _ | C. albicans (2) | died |
a All patients had TPN administration and CVC.
b Abbreviations: DOS, duration of stay; ICU, intensive care unit; TBSA, total body surface area; y, years; d, days.
| Characteristics | Patients With Candidemia (n = 13) | Without Patients Candidemia (n = 100) | P Value |
|---|---|---|---|
| Age, y | 33.8 ± 24.8 | 34.4 ± 19.5 | 0.51 |
| TBSA, % | 39.9 ± 17.6 | 41.5 ± 18.7 | 0.73 |
| Hospital DOS, d | 41.2 ± 19.7 | 22.9 ± 11.7 | 0.0003 |
| ICU DOS, d | 37.5 ± 19.2 | 16.2 ± 12.9 | < 0.0001 |
| CVC | 13 (100) | 83 (83) | 0.13 |
| No. antibiotics | 4.8 | 4 | 0.07 |
| Mechanical ventilation | 8 (61.5) | 40 (40) | 0.07 |
| TPN | 13 (100) | 81 (81) | 0.1 |
| Mortality | 9 (69.2) | 36 (36) | 0.04 |
a Abbreviations: CVC, central venous catheter; DOS, duration of stay; ICU, intensive care unit; TBSA, total body surface area; TPN, total parenteral nutrition; y, years; d, days.
4.2. Candida In Blood
4.3. Antifungal Susceptibility Testing
| Candida Species | No. (%) | MIC, µg/mL b | |||
|---|---|---|---|---|---|
| Amphotericin B | Voriconazole | Fluconazole | Caspofungin | ||
| C. parapsilosis | 13 (48) | 0.002 - 0.38 (0.06) | 0.125 - 0.047 (0.06) | 0.064 - 3 (1.17) | > 32 |
| C. tropicalis | 7 (26) | 0.016 - 0.032 (0.01) | 0.016 - 0.032 (0.04) | 0.125 - 0.25 (0.22) | 1 (0.96) |
| C. guilliermondii | 4 (15) | 0.002 - 0.094 (0.01) | 0.04 - 0.064 (0.02) | 0.38 - 6 (1.92) | 0.38 - 32 < (4.51) |
| C. albicans | 3 (11) | 0.002 - 0.047 (0.064) | 0.004 - 0.125 (0.03) | 0.19 - 0.38 (0.3) | 0.5 - 1.5 (1) |
a Abbreviation: MIC, minimal inhibitory concentration.
b Range (Geometric Mean).